Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Isoenzyme as tumor marker]

H Ohta1, H Watanabe, N Sawabu

  • 1Department of Internal Medicine, Kanazawa University.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|May 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cloning, subcellular localization and expression of CHL1, a subunit of magnesium-chelatase in soybean.

Biochemical and biophysical research communications·1995
Same author

[A resected case of focal nodular hyperplasia of the liver which could be diagnosed before operation].

Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology·1995
Same author

Molecular characterization of fusion regulatory protein-1 (FRP-1) that induces multinucleated giant cell formation of monocytes and HIV gp160-mediated cell fusion. FRP-1 and 4F2/CD98 are identical molecules.

Journal of immunology (Baltimore, Md. : 1950)·1995
Same author

[Evaluation of early colorectal cancer with submucosal invasion based on histological architecture].

Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology·1995
Same author

CT-defined large subcortical infarcts: correlation of location with site of cerebrovascular occlusive disease.

AJNR. American journal of neuroradiology·1995
Same author

[Pharmacological and biochemical investigation of intracavital fluorinated pyrimidine chemotherapy].

Gan to kagaku ryoho. Cancer & chemotherapy·1995
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Cancerous isoenzymes like alkaline phosphatase (ALP) and gamma-glutamyltranspeptidase (gamma-GTP) show promise as tumor markers. These biomarkers aid in diagnosing cancers such as hepatocellular carcinoma (HCC) and prostatic cancer.

Area of Science:

  • Biochemistry
  • Oncology
  • Clinical Diagnostics

Context:

  • Cancerous isoenzymes are increasingly studied for their diagnostic potential in various malignancies.
  • Alkaline phosphatase (ALP) and gamma-glutamyltranspeptidase (gamma-GTP) are key enzymes investigated for tumor-specific expression.
  • Current diagnostic markers have limitations, including low positive rates for some cancers.

Purpose:

  • To review the utility of specific cancerous isoenzymes as diagnostic tumor markers.
  • To highlight the potential of variant ALP, placental ALP, gamma-GTP, and prostatic acid phosphatase (PAT) in cancer detection.
  • To assess the specificity and positivity rates of these isoenzymes in different malignant tumors.

Summary:

  • Variant ALP is a specific marker for hepatocellular carcinoma (HCC).

Related Experiment Videos

  • Placental ALP is detected in various malignancies, with high positivity in seminoma.
  • A novel gamma-glutamyltranspeptidase (gamma-GTP) isoenzyme shows high specificity for HCC (approx. 60% positivity).
  • Serum prostatic acid phosphatase (PAT) is a useful marker for prostatic cancer.

    • Impact:

    • These isoenzymes offer potential for improved and specific cancer diagnosis.
    • Identification of sensitive and specific tumor markers can enhance early detection and patient management.
    • Further research into cancerous isoenzymes can lead to advancements in oncological diagnostics.